{"organizations": [], "uuid": "c955e902df9272c5d8f6129eff20507888ef1113", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-aralez-pharmaceuticals-says-unit-e/brief-aralez-pharmaceuticals-says-unit-entered-into-modification-of-contract-idUSFWN1RI0OZ", "country": "US", "domain_rank": 408, "title": "BRIEF-Aralez Pharmaceuticals Says Unit Entered Into Modification Of Contract", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-06T00:42:00.000+03:00", "replies_count": 0, "uuid": "c955e902df9272c5d8f6129eff20507888ef1113"}, "author": "", "url": "https://www.reuters.com/article/brief-aralez-pharmaceuticals-says-unit-e/brief-aralez-pharmaceuticals-says-unit-entered-into-modification-of-contract-idUSFWN1RI0OZ", "ord_in_thread": 0, "title": "BRIEF-Aralez Pharmaceuticals Says Unit Entered Into Modification Of Contract", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-aralez pharmaceuticals says unit", "sentiment": "negative"}, {"name": "brief-aralez pharmaceuticals says unit entered into", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}, {"name": "modification of contract reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "aralez pharmaceuticals inc", "sentiment": "none"}, {"name": "va national", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 5 (Reuters) - Aralez Pharmaceuticals Inc:\n* ARALEZ PHARMA - UNIT ENTERED INTO MODIFICATION OF CONTRACT PURSUANT TO WHICH U.S. EXERCISED SECOND RENEWAL OPTION UNDER THAT VA NATIONAL CONTRACT\n* ARALEZ PHARMA SAYS CONTRACT MODIFICATION EXTENDS TERM OF AGREEMENT TO APRIL 28, 2019 - SEC FILING\n* ARALEZ PHARMA - MODIFICATION INCLUDES SAME PRICING TERMS DURING APRIL 29, 2017 THROUGH APRIL 28 ANNUAL TERM EXCEPT FOR PRICE DECREASE TO 200MG SKUS Source text - bit.ly/2EnPFGc Further company coverage:\n ", "external_links": [], "published": "2018-04-06T00:42:00.000+03:00", "crawled": "2018-04-06T01:07:10.009+03:00", "highlightTitle": ""}